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Abstract 
Current treatments for Human African Trypanosomiasis (HAT) are limited in their application, have 
undesirable dosing regimens and unsatisfactory toxicities highlighting the need for the development 
of a safer drug pipeline. Our medicinal chemistry programme in developing rapidly accessible and 
modifiable heterocyclic scaffolds led to the design and synthesis of novel substituted 
benzothiophenes, with 6-benzimidazol-1-ylbenzothiophene derivatives demonstrating significant 
antitrypanosomal activities (IC50 <1 µM) against Trypanosoma brucei rhodesiense and no toxicity 
towards mammalian cells. 
 
1. Introduction 
Human African Trypanosomiasis, also known as sleeping sickness is caused by infection with 
Trypanosoma brucei rhodesiense (T.b.r) or Trypanosoma brucei gambiense (T.b.g) parasites. During 
the haemolymphatic phase, trypomastigotes circulate within the blood and lymphatic system. If not 
treated sufficiently, the neurological phase ensues as parasites penetrate the blood brain barrier 
thus infecting the central nervous system from which patient recovery is unlikely. Current treatment 
for T.b.r is dated and potentially lethal consisting of Suramin for the haemolymphatic phase and 
arsenic based melarsoprol for the neurological phase. These treatments require complicated dosing 
regimens and related side-effects such as reactive encephalopathy have proven fatal in up to 9% of 
patients [1]. Clinical advancements in antitrypanosomal drug development have been limited and 
resistance is increasing requiring the development of a new drug pipeline to replace existing 
therapies. Recent literature findings have included the development of 3-nitrotriazole based 
piperazides exhibiting appreciable in vitro activity against T.b.r parasites as well as series of hybrids 
of bile acids and Cinchona alkaloids demonstrating high in vitro activities against Trypanosoma brucei 
brucei [2, 3].  
 
Developing rapidly accessible fluorinated heterocyclic scaffolds [4, 5] with potential for further 
elaboration is thematic of our medicinal chemistry programme. Benzothiophene ring systems 
represent privileged scaffolds in medicinal chemistry and have been incorporated into: reverse 
transcriptase inhibitors; tubulin binders to inhibit microtubule formation; and antiprotozoal agents 
[6, 7, 8, 9, 10]. Our investigations highlighted in this article yielded diversely substituted fluorinated 
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benzothiophene scaffolds using aromatic nucleophilic substitution reactions (SNAr) of perfluorinated 
building blocks [11]. SNAr of perfluorinated arenes occur readily with a wide range of nucleophiles 
and often proceed under mild conditions without the need for transition metal catalysis [12]. The 
substitution patterns available by sequential replacement of fluorine differ from those afforded by 
electrophilic reaction protocols and allow structurally diverse derivatives to be prepared according 
to drug design strategies [13, 14]. Retaining fluorine is also desirable property in drug design since 
fluorine can improve metabolic stability due to the strength of the C-F bond (ca. 480 kJmol
-1
), whilst 
its small size (van der Waals radius, 147 pm) and high electronegativity impart desirable properties 
to a molecule which can significantly alter biological response [15, 16]. 
  
2. Methods and Results 
2.1 Syntheses 
Continuing our interest in preparing condensed sulfur containing heterocycles [17] from 
perfluoroarene precursors, firstly, tetrafluorobenzaldehydes 2a-e suitable for ring annelation 
reactions to construct the benzothiophene derivatives were prepared through the reaction of 
pentafluorobenzaldehyde 1 with a range of nucleophiles (Scheme 1) including two diazoles, a phenol 
and two thiols [18]. Treatment of the aldehydes 2 with α-mercaptocarbonyl compounds 3a or 3b 
was expected to lead to addition of the thiol to the 2-position of the benzaldehyde and allow 
condensation of the active methylene group with the adjacent aldehyde to form a fused thiophene 
ring 5, since thieno[2,3-c]pyridines have been prepared by a related method involving cyclisation 
onto a nitrile [19].
 
 
In practice, pentafluorobenzaldehyde reacted smoothly with selected diazoles, arenethiols and 2-
bromophenol to the form a series of 4-substituted benzaldehydes 2 in good yields. Addition at the 4-
position is in line with the usual orientation of addition observed for perfluorinated arenes [20].
 
Treatment of the benzaldehydes with either methyl α-mercaptoacetate 3a or 2’-
mercaptoacetophenone 3b in the presence of triethylamine as base led to the clean conversion to 
the 6-substituted-4,5,7-trifluorobenzothiophenes 5aa-5be in moderate to excellent yields. 
Treatment of pentafluorobenzaldehyde 1 with two equivalents of 3a or 3b led to direct formation of 
5af and 5bf in reasonable yields, in which the thiols most likely added consecutively to the 4- and 2-
positions of the aldehyde. Subsequently, the intramolecular reaction of the 2-substituent with the 
adjacent aldehyde group would have resulted in cyclisation forming the benzothiophene scaffold in 
a one-pot procedure. The intermediate 2-sulfanyl benzaldehydes 4a/b were not isolated. The 
structures of the new compounds were fully in accord with their analytical and spectroscopic 
properties. Computational studies to predict oral druglikeness demonstrated no compound within 
this study violated more than one of the parameters constituting Lipinski’s rule of 5 and all fall within 
acceptable limits of rotational bond count and polar surface area [21, 22, 23, 24].
 
The structure of 
compound 5bb was confirmed by single crystal X-ray diffraction analysis, with the molecular 
structure shown in Figure 1 [25, 26, 27]. 
2.2 Antitrypanosomal and Antiproliferative Activity  
Synthesised compounds (Table 1) were screened in a phenotypic assay against Trypanosoma brucei 
rhodesiense (STIB 900) and cytotoxicities determined against MCF7 cells [28].
 
 
 
2.2.1 6-Substituted-benzothiophene-2-carboxylate derivatives 
Compound 5ad, synthesised bearing a 6-(2-bromophenylsufanyl) group demonstrated moderate 
trypanocidal activity with an IC50 value of 11.9 µM. Compound 5ac was prepared with a 6-(2-
bromophenoxy) group and gave an IC50 value of 30 µM, with a similar toxicity value against the MCF7 
cell line. The bromophenyl groups in these two compounds were strategically designed to allow 
further modification of the scaffold by halogen-lithium exchange which would allow ring forming 
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reactions. The results of such reactions will be reported in due course alongside comparative 
bioactivity data. Compound 5aa, the 6-imidazolyl substituted analogue did not demonstrate 
trypanocidal activity, nor did the 6-(4-tert-butylphenylsulfanyl) derivative 5ae. Compound 5af, the 6-
benzoylmethylsulfanyl analogue, showed moderate activity but interestingly, the 6-benzimidazolyl 
analogue 5ab demonstrated respectable trypanocidal activity with an IC50 value of 0.60 µM, 
significantly greater than aforementioned benzothiophene-2-carboxylate derivatives screened. The 
selectivity ratio of trypanocidal activity against MCF7 cells was greater than 20 fold, making this 
compound a successful hit within the 2-carboxylate derivatives. 
 
2.2.2 2-Benzoyl-benzothiophene derivatives 
In the ketone series, compound 5bd, the 2-benzoylbenzothiophene with a bromophenyl sulfanyl 
substituent showed comparable antiparasitic and cytotoxic activity to 5ad with an IC50 value of 9.8 
µM. Similarly, the imidazolyl substituted compound 5ba showed an increase in trypanocidal activity 
with an IC50 value of 33.0 µM in relation to its carboxylate analogue 5aa, but not to the extent of 
being classified as a hit compound. Likewise for the pair 5be/5ae the ketone showed 2-fold better 
antiparasitic activity than the corresponding carboxylate, while for 5bf/5af comparable trypanocidal 
activity was observed in the region of 10 µM and above. Importantly, the benzimidazole-containing 
compound 5bb demonstrated a trypanocidal IC50 value of 0.53 µM, comparable to the 2-carboxylate 
5ab and significantly more active than the other ketones evaluated. The selectivity ratio of 
trypanocidal activity of 5bb against MCF7 cells was almost than 50 fold, making this compound a 
successful hit within the ketone derivatives. 
 
3. Conclusion 
A library of novel and easily accessible fluorinated benzothiophenes were synthesised by employing 
SNAr substitution reactions of perfluorinated building blocks. Noticeably, 5ab and 5bb were identified 
as hit compounds with IC50 values <1 µM against Trypanosoma brucei rhodesiense and no interpreted 
toxicity against MCF7 cells. Interestingly, both benzothiophene scaffolds were substituted with a 
benzimidazole moiety. Our hit compounds hold potential for further modification and the 
benzothiophene scaffold serves as a point of expansion on our current library. Results from further 
experiments will be published in due course. 
 
4. Experimental 
Solvents used were commercially available. Flash column chromatography was carried out on Merck 
Kiesel 60 silica gel and TLC analysis performed on Merck TLC silica gel 60 F254 aluminum backed 
plates. NMR spectra were recorded in CDCl3 at 400 MHz (
1
H NMR), 376 MHz (
19
F NMR) or 100 MHz 
(
13
C NMR) on a Bruker Advance 400 MHz instrument or a Joel JNM-ECS400 instrument. IR spectra 
were recorded on a PerkinElmer Spectrum 65, FT-IR Spectrometer. HRMS spectra were recorded 
using a Thermofisher Exactive (orbitrap) mass spectrometer with ESI as the ionization mode, or were 
recorded at the EPSRC UK National Mass Spectrometry Facility at Swansea University. Melting points 
were recorded using an Electro thermal-IA 9100 melting point instrument. Elemental analyses were 
determined on a Perkin-Elmer 2400 analyser. 
 
4.1 Synthesis of Compounds 2a-e 
A solution of pentafluorobenzaldehyde (2 mmol) in THF (2.5 ml) was added to a solution of the 
relevant nucleophile (2-4 mmol) in THF (2.5 ml), with Et3N (4-10 mmol) used in the reactions of 
compounds 2c-e. The resulting solution was stirred at room temperature for up to 24 h. The reaction 
mixture was poured into deionised water and was extracted with ethyl acetate (15 ml x 3). Organic 
extracts for compounds 2c-e were further washed with 0.2 M HCl (aq) and deionised water, 
combined and dried over NaSO4. The solution was concentrated and the crude residue purified by 
column chromatography (elution with light petroleum/ethyl acetate).  
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4-Imidazol-1-yl-tetrafluorobenzoaldehyde (2a) [18] 
Yield 68%, red oil. NMR δH (CDCl3), 10.31 (1H, s, CHO), 7.88 (1H, s), 7.32 (1H, s,), 7.29 (1H, s); NMR δF 
(CDCl3), 19.4-19.2 (2F, m), 14.9-15.0 (2F, m); NMR δc (CDCl3), 181.5 (CHO), 147.4 (ddd, J = 260, 11, 4 
Hz), 140.7 (ddd, J = 255, 12, 5 Hz), 137.5, 130.5 (C-4’), 122.0 (t, J = 12 Hz), 119.7, 113.6 (t, J = 10 Hz); 
IR, νmax /cm
-1
 1712 (CHO); MS, m/z found 245.0332, C10H5F4N2O, (M+H
+
) requires 245.0333. 
 
4-Benzimidazol-1-yl-tetrafluorobenzoaldehyde (2b) 
Yield 62%, yellow solid, m.p. 160-162 
o
C. NMR δH (CDCl3), 10.42 (1H, s, CHO), 8.09 (1H, t, J = 1.8 Hz), 
7.96-7.92 (1H, m), 7.47-7.42 (2H, m), 7.33-7.29 (1H, m); NMR δF (CDCl3), 19.5-19.4 (2F, m), 18.2-18.1 
(2F, m); NMR δc (CDCl3), 181.6 (CHO), 147.3 (ddd, J = 260, 12, 5 Hz), 143.2, 142.0 (ddd, J = 250, 14, 6 
Hz), 141.9, 132.7, 125.0, 124.1, 121.0, 120.8 (d, J = 10 Hz), 114.6 (d, J = 10 Hz), 110.7 (t, J = 3 Hz); IR, 
νmax /cm
-1
 1705 (CHO); MS, m/z found 295.0488, C14H7F4N2O, (M+H
+
) requires 295.0489; elemental 
analysis, C14H6F4N2O requires: C, 57.15; H, 2.06; N, 9.52; found: C, 57.19; H, 2.16; N, 9.37.  
 
4-(2-Bromophenoxy)-2,3,5,6-tetrafluorobenzaldehyde (2c) 
Yield 62%, white solid, m.p. 48-50 
o
C. NMR δH (CDCl3), 10.31 (1H, s, CHO), 7.67 (1H, dd, J = 8.0, 1.6 
Hz), 7.31 (1H, td, J = 8.0, 1.6 Hz), 7.11 (1H, td, J = 8.0, 1.2 Hz,), 6.94 (1H, d, J = 8.0 Hz); NMR δF (CDCl3), 
17.1-17.0 (2F, m), 8.4-8.3 (2F, m); NMR δc (CDCl3), 182.0 (CHO), 153.0, 147.6 (ddd, J = 260, 17, 6 Hz), 
140.6 (dd, J = 250, 12 Hz), 134.2, 128.8, 126.3, 125.9, 117.3, 112.6, 111.1 (t, J = 10 Hz); IR, νmax /cm
-1
 
1705 (CHO); MS, m/z found 348.9478, C13H6
79
BrF4O2, (M+H
+
) requires 348.9482; elemental analysis, 
C13H4BrF4O2 requires: C, 44.85; H, 1.16; found: C, 44.73; H, 1.16. 
 
4-[(2-Bromophenyl)thio]-2,3,5,6-tetrafluorobenzaldehyde (2d) 
Yield 62%, white solid, m.p. 88-90
o
C. NMR δH (CDCl3), 10.33 (1H, s CHO), 7.65 (1H, dd, J = 8.0, 1.2 Hz), 
7.38 (1H, d, J = 7.6 Hz), 7.30 (1H, td, J = 7.6, 1.2 Hz), 7.23 (1H, td, J = 7.6, 1.6 Hz); NMR δF (CDCl3), 
29.7-29.6 (2F, m), 17.4-17.3 (2F, m); NMR δc (CDCl3), 182.2 (CHO), 146.4 (dd, J = 260, 13 Hz), 146.1 
(dd, J = 260, 11 Hz), 133.8, 132.7, 132.0, 130.1, 128.3, 125.9, 125.5 (t, J = 18 Hz), 114.7 (t, J = 11 Hz); 
IR, νmax /cm
-1
 1705 (HC=O); MS, m/z found 364.9251, C13H6
79
BrF4OS, (M+H
+
) requires 364.9253; 
elemental analysis, C13H5BrF4OS requires: C, 42.76; H, 1.38; found: C, 42.73; H, 1.35.  
 
4-[(4-(tert-Butyl)phenyl)thio]-2,3,5,6-tetrafluorobenzaldehyde (2e) 
Yield 73%, yellow solid, m.p. 42-44
o
C NMR δH (CDCl3), 10.30 (1H, s, CHO), 7.44-7.36 (4H, m), 1.33 (9H, 
s); NMR δF (CDCl3), 29.1-29.2 (2F, m), 147.0-16.9 (2F, m); NMR δc (CDCl3), 182.3 (s, CHO), 152.6, 
146.6 (dd, J = 260, 16 Hz), 146.1 (dd, J = 260, 10 Hz), 132.3, 127.2, 126.7, 123.4 (t, J = 18 Hz), 114.4 (t, 
J = 10 Hz), 34.7, 31.2; IR, νmax /cm
-1
 1705 (CHO); MS, m/z found 343.0778, C17H15F4OS, (M+H
+
) 
requires 343.0774; elemental analysis, C17H14F4OS requires: C, 59.64; H, 4.12; found: C, 59.61; H, 
4.06.  
 
4.2 Synthesis of Compound 3b [29] 
2-Bromoacetophenone (2 mmol) was added to a solution of potassium thioacetate (2 mmol) in THF 
(5 ml). The reaction was stirred at 40 °C for 24 h. The mixture was poured into deionised water and 
extracted with ethyl acetate (15 ml x 3). The combined extracts were dried with sodium sulfate. The 
residue was treated with 1M NaOH (1.96 ml) in methanol (4 ml). The solution was stirred at room 
temperature for 14 h and then poured into deionised water and neutralised with 1 M HCl. The 
neutralised mixture was extracted with ethyl acetate (15 ml x 3). The combined extracts were dried 
over sodium sulfate. The crude residue was purified by column chromatography (elution with light 
petroleum/ethyl acetate). 
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2-Mercapto-1-phenylethanone (3b) 
Yield 37%, yellow oil. NMR δH (CDCl3), 8.01-7.98 (2H, m, H-2, H-6), 7.63 (1H, tt, J = 7.6, 1.2 Hz, H-4), 
7.52 (2H, t, J = 8 Hz, H-3, H-5), 4.00 (2H, d, J = 7.6 Hz, H-2’), 2.16 (1H, t, J = 7.6 Hz, SH); MS, m/z found 
153.0363, C8H9OS, (M+H
+
) requires 153.0369. 
 
4.3 Syntheses of Compounds 5aa-5ae 
Compounds 2a-e (2 mmol) and Et3N (5 mmol) in THF (6 ml) were treated dropwise with methyl 
mercaptoacetate (3a, 2 mmol) with ice cooling. The mixtures were stirred at room temperature for 
up to 16 h and then poured into deionised water and were extracted with ethyl acetate (15 ml x 3). 
The combined organic extracts were washed with 0.2 M HCl (aq) and deionised water and dried over 
NaSO4. The crude products were purified by column chromatography (elution with light 
petroleum/ethyl acetate). 
 
Methyl-4,5,7-trifluoro-6-(1H-imidazol-1-yl)benzo[b]thiophene-2-carboxylate (5aa) 
Yield 70%, white solid, m.p. 146-148 
o
C. NMR δH (CDCl3), 8.17 (1H, d, J = 3.2 Hz), 7.81 (1H, s), 7.29 
(1H, s), 7.28 (1H, s), 3.99 (3H, s); NMR δF (CDCl3), 36.2 (1F, d, J = 19 Hz), 19.8 (1F, t, J =19 Hz), 14.6 (1F, 
d, J= 20 Hz); NMR δC (CDCl3), 171.1, 161.5, 146.3 (ddd, J = 248, 4, 3 Hz), 143.5 (ddd, J= 251, 13, 4 Hz), 
141.8 (ddd, J = 245, 15, 3 Hz), 137.9, 130.0, 128.6 (ddd, J = 18, 6, 3 Hz), 125.6 (ddd, J = 21, 6, 3 Hz), 
125.1 (d, J = 6 Hz), 120.4, 114.6 (t, J = 16 Hz), 53.2; IR, νmax /cm
-1
 1728 (C=O), 1265 (C-O); MS, m/z 
found 313.0264, C13H7F3N2OS, (M+H
+
) requires 313.0253; elemental analysis, C13H7F3N2O2S requires: 
C, 50.00; H, 2.26; N, 8.97; found: C, 49.91; H, 2.19; N, 8.88.  
 
Methyl-6-(1H-benzo[d]imidazol-1-yl)-4,5,7-trifluorobenzo[b]thiophene-2-carboxylate (5ab) 
 Yield 57%, white solid, m.p. 178-179 °C. NMR δH (CDCl3), 8.26 (1H, d, J = 3.2 Hz), 8.10 (1H, s), 7.92 
(1H, dd, J = 7.6, 2.4 Hz), 7.42-7.37 (2H, m), 7.30 (1H, d, J = 8.0 Hz), 4.02 (3H, s); NMR δF (CDCl3), 38.9 
(1F, d, J=19 Hz), 20.2 (1F, t, J=19 Hz), 16.8 (1F, d, J=19 Hz); NMR δc (CDCl3), 171.1, 161.5, 147.6 (dt, J = 
251, 4 Hz), 143.1, 142.8, 142.7 (dt, J = 249, 5 Hz), 142.5 (dt, J = 251, 5 Hz), 138.2, 133.8, 129.5 (ddd, J 
= 19, 7, 2 Hz), 125.8 (ddd, J = 17, 5, 2 Hz), 125.3 (d, J = 5 Hz), 124.4, 123.5, 120.8, 112.9 (t, J = 6 Hz), 
110.4, 53.2; IR, νmax /cm
-1
 1720 (C=O), 1249 (C-O); MS, m/z found 363.0402, C17H9F3N2O2S, (M+H
+
) 
requires 363.0410; elemental analysis, C17H9F3N2O2S requires: C, 56.51; H, 2.21; N, 7.75; found: C, 
56.36; H, 2.56; N, 7.62. 
 
Methyl-6-(2-bromophenoxy)-4,5,7-trifluorobenzo[b]thiophene-2-carboxylate (5ac) 
Yield 78%, white solid, m.p. 126-128 °C. NMR δH (CDCl3), 8.19 (1H, d, J = 3.2 Hz), 7.67 (1H, dd, J = 8, 
1.6 Hz, H-3”), 7.24 (1H, td, J = 7.6 Hz, 1.6 Hz, H-5”), 7.03 (1H, td, J = 7.6, 1.6 Hz, H-4”), 6.78 (1H, dd, J 
= 7.6, 0.8 Hz), 4.01 (3H, s); NMR δF (CDCl3), 29.9 (1F, dd, J =17, 3 Hz), 19.4 (1F, dd, J =19, 17 Hz), 10.3 
(1F, d, J = 19 Hz); NMR δC (CDCl3), 161.9, 154.1, 146.0 (dt, J = 248, 4 Hz),), 142.8 (ddd, J = 254, 12, 4 
Hz), 141.8 (ddd, J = 248, 13, 3 Hz), 136.3, 134.1, 131.5 (t, J = 14 Hz), 128.7, 125.9 (dd, J = 18, 4 Hz), 
125.6 (dd, J = 19, 4 Hz), 125.3 (d, J = 6 Hz), 125.0, 115.5, 111.9, 53.1; IR, νmax /cm
-1
 1720 (C=O), 1257 
(C-O); MS, m/z found 416.9400, C16H9BrF3O3S, (M+H
+
) requires 416.9402; elemental analysis, 
C16H8BrF3O3S requires: C, 46.06; H, 1.93; found: C, 46.07; H, 1.93.  
 
Methyl-6-[(2-bromophenyl)thio]-4,5,7-trifluorobenzo[b]thiophene-2-carboxylate (5ad) 
Yield 66%, white solid, m.p. 143-145 °C. NMR δH (CDCl3), 8.20 (1H, d, J = 3.2 Hz), 7.60 (1H, dd, J = 8.0 
Hz, 1.2 Hz), 7.20 (1H, td, J = 7.2 Hz, 1.2 Hz), 7.10 (1H, td, J = 7.2, 1.2 Hz), 6.94 (1H, d, J = 7.6 Hz), 4.02 
(3H, s); NMR δF (CDCl3), 53.7 (1F, dd, J=17, 3 Hz), 29.7 (1F, d, J=21 Hz), 18.9 (1F, t, J=20 Hz); NMR δC 
(CDCl3), 161.9, 153.2 (d, J = 248 Hz), 143.7 (ddd, J = 250, 16, 5 Hz), 141.3 (d, J = 245, 21, 10 Hz), 138.0, 
135.4, 133.4, 130.5 (dd, J = 17, 7 Hz), 128.9, 128.0, 128.0 (d, J = 7 Hz), 125.9-125.4 (m), 125.4 (d, J = 5 
Hz), 122.7, 109.2 (t, J = 21 Hz), 53.2; IR, νmax /cm
-1
 1720 (C=O), 1265 (C-O); MS, m/z found 432.9129, 
C16H9O2 BrF3S2, (M+H
+
) requires 432.9174; elemental analysis, C16H8BrF3O2S2 requires: C, 44.35; H, 
1.86; found: C, 44.18; H, 1.74.  
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Methyl-6-((4-(tert-butyl)phenyl)thio)-4,5,7-trifluorobenzo[b]thiophene-2-carboxylate  (5ae) 
Yield 76%, white solid, m.p. 127-129 °C. NMR δH (CDCl3), 8.15 (1H, d, J = 3.2 Hz), 7.37-7.31 (4H, m), 
4.00 (3H, s), 1.31 (9H, s); NMR δF (CDCl3), 52.6 (1F, d, J = 17 Hz), 29.3 (1F, d, J = 23 Hz), 18.2 (1F, t, J = 
20 Hz); NMR δc (CDCl3), 161.9, 152.9 (dt, J = 248, 5Hz), 151.1, 147.0 (ddd, J = 245, 13, 4 Hz), 142.5 
(ddd, J = 253, 18, 4 Hz), 137.4, 130.5, 130.2 (ddd, J = 22, 9, 4 Hz), 130.0, 126.4 (C-3”, C-5”), 125.6-
125.2 (m), 125.3 (d, J = 5 Hz), 111.8 (t, J = 22 Hz), 53.0, 34.6, 31.2; IR, νmax /cm
-1
 1712 (C=O), 1249 (C-
O); MS, m/z found 411.0696, C20H18F3O2S2, (M+H
+
) requires 411.0695; elemental analysis, 
C20H17F3O2S2 requires: C, 58.52; H, 4.17; found: C, 58.40; H, 4.12. 
 
Methyl-4,5,7-trifluoro-6-((2-methoxy-2-oxoethyl)thio)benzo[b]thiophene-2-carboxylate (5af) 
Methyl mercaptoacetate (4 mmol) was added dropwise to a solution of pentafluorobenzaldehyde (2 
mmol) and Et3N (5 mmol) in THF (5 ml) with ice cooling. The mixture was stirred at room 
temperature for 16 h. The reaction was poured into deionised water and was extracted with ethyl 
acetate (15 ml x 3). The combined extracts were washed with 0.2 M HCl solution and deionised 
water successively and dried with sodium sulfate. The product was purified by silica column 
chromatography (elution with light petroleum/ethyl acetate). Yield 62%, white solid, m.p. 118-
120 °C. NMR δH (CDCl3), 8.09 (1H, d, J = 3.2 Hz), 3.98 (3H, s), 3.69 (3H, s), 3.65 (2H, s); NMR δF (CDCl3), 
52.4 (1F, dd, J = 18, 3 Hz), 28.5 (1F, d, J = 21 Hz), 18.3 (1F, dd, J = 21, 18 Hz); NMR δc (CDCl3), 169.2, 
161.9, 153.1 (d, J = 246 Hz), 147.3 (ddd, J = 242, 15, 4 Hz), 142.4 (ddd, J = 253, 14, 4 Hz), 137.6, 130.4 
(ddd, J = 15, 7, 4 Hz), 125.6-125.2 (m), 125.5 (d, J = 7 Hz), 110.1 (t, J = 22 Hz), 53.1, 52.8, 36.1; IR, νmax 
/cm
-1
 1728 (C=O), 1273 (C-O); MS, m/z found 350.9969, C13H10F3O4S2, (M+H
+
) requires 350.9967; 
elemental analysis, C13H9F3O4S2 requires: C, 44.57; H, 2.59; found: C, 44.40; H, 2.53. 
 
4.4 Syntheses of Compounds 5ba-5be 
Following the method for compounds 5aa-ae, reaction of compounds 2a-e (2 mmol) and 3b (0.304 g, 
2 mmol) provided compounds 5ba-be, purified by flash column chromatography eluting with light 
petroleum/ethyl acetate. 
 
Phenyl-(4,5,7-trifluoro-6-(1H-imidazol-1-yl)benzo[b]thiophen-2-yl)methanone (5ba) 
Yield 49%, cream solid, m.p. 132-134 °C. NMR δH (CDCl3), 7.98 (1H, d, J = 3.2 Hz), 7.92 (2H, d, J = 7.2 
Hz), 7.87 (1H, s), 7.67 (1H, tt, J = 7.6, 1.6 Hz), 7.57 (2H, t, J = 7.6 Hz), 7.31 (1H, s), 7.28 (1H, s); NMR δF 
(CDCl3), 36.6 (1F, d, J = 19 Hz), 20.2 (1F, t, J = 17 Hz), 14.7 (1F, d, J = 17 Hz); NMR δC (CDCl3), 188.1, 
147.6, 146.5 (d, J = 255 Hz), 143.1 (ddd, J = 255, 16, 5 Hz), 141.8 (dd, J = 250, 14 Hz), 138.0, 136.6, 
133.6, 129.9, 129.4, 129.2 (dd, J = 19, 7 Hz), 129.0, 126.2 (dd, J = 19, 7 Hz), 125.6 (d, J = 5 Hz), 120.5, 
114.8 (t, J = 15 Hz); IR, νmax /cm
-1
 1643 (C=O); MS, m/z found 359.0454, C18H10F3ON2S, (M+H
+
) 
requires 359.0460; elemental analysis, C18H9F3N2OS requires: C, 60.33; H, 2.53; N, 7.82; found: C, 
60.08; H, 2.60; N, 7.68.  
 
6-(1H-benzo[d]imidazol-1-yl)-4,5,7-trifluorobenzo[b]thiophen-2-yl(phenyl)methanone (5bb) 
Yield 51%, orange solid, m.p. 140-142 °C. NMR δH (CDCl3), 8.09 (1H, s), 8.04 (1H, d, J = 3.2 Hz), 7.94 
(2H, d, J = 7.8 Hz), 7.93-7.89 (1H, m) 7.70 (1H, t, J = 7.2 Hz), 7.59 (2H, t, J = 7.6 Hz), 7.42-7.34 (2H, m), 
7.31-7.27 (1H, m); NMR δF (CDCl3), 39.34 (1F, d, J = 17 Hz), 20.6 (1F, t, J = 20 Hz), 16.9 (1F, d, J = 20 
Hz); NMR δc (CDCl3), 188.2, 147.8 (d, J = 251 Hz), 147.7, 143.1 (ddd, J = 254, 13, 4 Hz), 143.2, 142.8, 
142.7 (dd, J = 249, 14 Hz), 136.6, 133.8, 133.6, 129.9 (dd, J = 17, 4 Hz), 129.5, 129.0, 126.2 (ddd, J = 
18, 4, 3 Hz), 125.7 (d, J = 6 Hz), 124.6, 123.6, 120.9, 113.3 (t, J = 16 Hz), 110.5; IR, νmax /cm
-1
 1643 
(C=O); MS, m/z found 409.0608, C22H12F3ON2S, (M+H
+
) requires 409.0617; elemental analysis, 
C22H11F3ON2S requires: C, 64.70; H, 2.69; N, 6.86; found: C, 64.47; H, 2.70; N, 6.96. 
 
6-(2-Bromophenoxy)-4,5,7-trifluorobenzo[b]thiophen-2-yl(phenyl)methanone (5bc) 
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Yield 48%, yellow solid, m.p. 110-112 °C. NMR δH (CDCl3), 7.95 (1H, d, J = 2.8 Hz), 7.92 (2H, d, J = 7.6 
Hz), 7.71-7.61 (2H, m), 7.56 (2H, t, J = 7.6 Hz), 7.21 (1H, t, J = 7.6 Hz), 7.01 (1H, t, J = 7.2 Hz), 6.76 (1H, 
d, J = 8.4 Hz); NMR δF (CDCl3), 30.3 (1F, d, J = 15 Hz), 19.6 (1F, t, J = 20 Hz), 10.5 (1F, d, J = 20 Hz); 
NMR δC (CDCl3), 188.4, 154.1, 146.1 (dd,  J = 249, 4 Hz), 146.0, 143.2 (ddd,  J = 251, 14, 3 Hz), 142.1 
(ddd,  J = 251, 14, 4 Hz), 136.9, 134.1, 133.3, 131.9 (t, J = 14 Hz), 129.4, 128.9, 128.7, 126.4 (dd , J = 
17, 4 Hz), 126.3-125.8 (m), 126.1 (d, J = 4 Hz), 125.1, 115.6, 112.0; IR, νmax /cm
-1
 1643 (C=O); MS, m/z 
found 462.9601, C21H11BrF3O2S, (M+H
+
) requires 462.9610; elemental analysis, C21H10BrF3O2S 
requires: C, 54.44; H, 2.18; found: C, 54.37; H, 2.04.  
 
6-(2-Bromophenyl)thio-4,5,7-trifluorobenzo[b]thiophen-2-yl(phenyl)methanone (5bd) 
Yield 46%, brown solid, m.p. 118-120 °C. NMR δH (CDCl3), 7.96 (1H, d, J = 3.2 Hz), 7.92 (2H, d, J = 7.2 
Hz), 7.68 (1H, t, J = 8.0 Hz). 7.59-7.54 (3H, m), 7.17 (1H, td, J = 7.2, 1.1 Hz), 7.08 (1H, td, J = 7.2, 1.5 
Hz), 6.94 (1H, d, J = 7.6 Hz); NMR δF (CDCl3), 54.0 (1F, d, J = 23 Hz), 29.8 (1F, d, J = 17 Hz), 19.1 (1F, t, J 
= 17 Hz); NMR δC (CDCl3), 188.5, 153.2 (d, J = 249 Hz), 147.4, 146.9 (dd, J = 249, 17 Hz), 142.9 (dd, J = 
256, 12 Hz), 136.7, 135.3, 133.5, 133.4, 131.2 (ddd, J = 18, 8, 4 Hz), 129.4, 129.1, 129.0, 128.2, 128.1, 
127.1-126.8 (m), 126.0 (d, J = 5 Hz), 122.9, 109.8 (t, J = 22 Hz); IR, νmax /cm
-1
 1635 (C=O); MS, m/z 
found 478.9370, C21H11BrF3OS2, (M+H
+
) requires 478.9381; elemental analysis, C21H10BrF3OS2 
requires: C, 52.62; H, 2.10; found: C, 52.45; H, 1.92. 
 
6-[(4-tert-Butylphenyl)thio]-4,5,7-trifluorobenzo[b]thiophen-2-yl(phenyl)methanone (5be) 
Yield 49%, red oil. NMR δH (CDCl3), 7.91 (2H, d, J = 2.0 Hz), 7.90 (2H, d, J = 7.6 Hz), 7.66 (1H, t, J = 7.6 
Hz). 7.55 (2H, t, J = 7.6 Hz), 7.31 (4H, AA’BB’ m), 1.25 (9H, s, H); NMR δF (CDCl3), 53.0 (1F, d, J = 17 
Hz), 29.4 (1F, d, J = 23 Hz), 18.3 (1F, t, J = 21 Hz); NMR δC (CDCl3), 188.6, 153.1 (d, J = 250 Hz), 151.2, 
147.0 (d, J = 250 Hz), 146.9, 142.7 (d, J = 250 Hz), 136.9, 133.4, 130.7, 130.6-130.4 (m), 130.0, 129.4, 
128.9, 126.7-126.3 (m), 126.5, 126.1 (d, J = 9 Hz), 112.3 (t, J = 19 Hz), 34.6, 29.8; IR, νmax /cm
-1
 1646 
(C=O); MS, m/z found 457.0895, C25H20F3ON2S2, (M+H
+
) requires 457.0902; elemental analysis, 
C25H19F3OS2 requires: C, 65.77; H, 4.19; found: C, 65.73; H, 4.46.  
 
2-[(2-Benzoyl-4,5,7-trifluorobenzo[b]thiophen-6-yl)thio]-1-phenylethanone (5bf) 
Following the same method for compound 5af, reaction of pentafluorobenzaldehyde (2 mmol) and 
3b (4 mmol) afforded compound 5bf after purification by chromatography eluting with light 
petroleum/ethyl acetate. Yield 21%, orange solid, m.p. 138-139 °C. NMR δH (CDCl3), 7.93-7.89 (5H, 
m), 7.67 (1H, t, J = 7.2 Hz), 7.61-7.53 (3H, m), 7.46 (2H, t, J = 7.8 Hz), 4.36 (2H, s); NMR δF (CDCl3), 
53.0 (1F, d, J = 20 Hz), 28.8 (1F, d, J = 20 Hz), 18.2 (1F, t, J = 19 Hz); NMR δC (CDCl3), 193.2, 188.6, 
153.1 (d, J = 246 Hz), 147.3 (ddd, J = 240, 16, 4 Hz), 146.9, 142.5 (ddd, J = 252, 18, 4 Hz), 136.8, 135.1, 
133.9, 133.4, 130.7 (dd, J = 18, 4 Hz), 129.4, 128.91, 128.88, 128.6, 126.0 (d, J = 6 Hz), 125.7 (dd, J = 
23, 6 Hz), 110.7 (t, J = 22 Hz), 40.6; IR, νmax /cm
-1
 1635 (C=O), 1666 (C=O); MS, m/z found 443.0374, 
C23H14F3O2S2, (M+H
+
) requires 443.0382; elemental analysis, C23H13F3O2S2.0.5H2O requires: C, 61.19; 
H, 3.12; found: C, 61.5; H, 2.83.  
 
4.5 Antitrypanosomal Activity Assays 
Trypanosoma brucei rhodesiense STIB 900, a clone of a population isolated in 1982 from a patient in 
Tanzania. Stock drug solutions were prepared in DMSO at 20 mg/ml and further diluted to the 
appropriate concentration using medium. Assays were performed in 96-well microtiter plates with 
each well containing 100 μl of parasite culture (1 x 10
3
 bloodstream forms) with serial drug dilutions 
at 37 °C for 72 h in 5% CO2. Each compound was tested in triplicate with 30 μg/ml the highest 
concentration of compound used and a 3-fold serial dilution was performed down to a suitable 
concentration to obtain an IC50 value. Control wells were without drug and blanks were medium 
only. After 72 h of incubation the plates were inspected to assure growth in control wells and to 
determine the minimum inhibitory concentration (MIC). Subsequently, 20 μl of Alamar Blue was 
added to each well and the plates incubated for another 2-4 h. Plates were read on a Gemini Plate 
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Reader (Molecular Devices) using an excitation wave length of 530 nm and an emission wave length 
of 580 nm (cut off 550 nm). IC50 values were calculated using Prism software. 
 
 
4.6 Antiproliferative Activity Assays 
Assays were conducted using the same protocol as described by Krystof et al. [28].
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Schemes 
 
 
 
Scheme 1. Overall reaction scheme to generate 2,6-Disubstituted-4,5,7-Trifluorobenzothiophenes 
Figures 
 
Figure 1. Crystal structure of 5bb 
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Tables 
  Activity (IC50 µM) 
Compound* Structure T.b.r MCF7 
5aa 
 
129.9 >100 
5ab 
 
0.60 >12 
5ac 
 
30.0 >25 
5ad 
 
11.9 >25 
5ae 
 
67.2 >50 
 
5af 
 
 
>10 >25 
5ba 
 
33.0 >60 
5bb 
 
0.53 >25 
5bc 
 
15.9 >25 
5bd 
 
9.8 >25 
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5be 
 
31.4 >25 
5bf 
 
>10 >50 
Melarsoprol  0.051 - 
Roscovitine   11 
 
Table 1. Synthesised 2,6-Disubstituted-4,5,7-Trifluorobenzothiophenes 
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• perfluorinated building blocks used in synthesis of heterocyclic scaffolds 
• SNAr substitution reactions employed to deliver 6-benzimidazol-1-ylbenzothiophenes  
• IC50  values of lead compounds were <1 µM against Trypanosoma brucei rhodesiense 
 
